Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136515 | 0.89 | PTGDR2 (0.52) | PTGDR2TBXA2RPTGDRPDK2CETP | |
| SCHEMBL138010 | 0.88 | PTGDR2 (0.51) | PTGDR2TBXA2RPTGDRPDK2CETP | |
| SCHEMBL138848 | 0.86 | PTGDR2 (0.48) | PTGDR2TBXA2RPTGDRPDK2CETP | |
| SCHEMBL142789 | 0.81 | PTGDR2 (0.56) | PTGDR2TBXA2RPTGDRCYP3A4CYP2C9 | |
| SCHEMBL137125 | 0.79 | PDK2 (0.43) | PTGDR2TBXA2RPTGDRPDK2CETP | |
| SCHEMBL138454 | 0.78 | PTGDR2 (0.58) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL136310 | 0.78 | PTGDR2 (0.66) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL153354 | 0.77 | PTGDR2 (0.50) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL140513 | 0.77 | PTGDR2 (0.65) | PTGDR2TBXA2RPTGDRCETPCYP3A4 | |
| SCHEMBL137267 | 0.76 | PDK2 (0.41) | PTGDR2TBXA2RPTGDRPDK2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158036-A1 | N,N-DISUBSTITUTED AMINOALKYLBIPHENYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885TBXA2R 12/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.